Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases
· Affibody and Chiesi Group will collaborate closely to develop novel Affibody[®] molecules as innovative treatments for respiratory diseases. · This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical needs. · Affibody will receive an upfront payment, future milestone payments, and royalties while retaining Nordic co-promotion rights.
Solna, Sweden, and Parma, Italy, February March 7, 2023 - Affibody AB (“Affibody”) and Chiesi Farmaceutici S.p.A (“Chiesi Group”) today announced the execution of a collaboration and licensing agreement